<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">Henrik Zetterberg</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>University of Gothenburg<br>UCL</td>
</tr>
<tr>
<td class="label">Country</td>
<td>Sweden/UK</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>200</td>
</tr>
<tr>
<td class="label">ORCID</td>
<td><a href="https://orcid.org/0000-0003-3939-6464" target="_blank">0000-0003-3939-6464</a></td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/als)</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>[Biomarkers](/mechanisms/biomarkers-ad), Neurofilament, [Tau](/mechanisms/tau-pathology), [Alpha-synuclein](/mechanisms/alpha-synuclein)</td>
</tr>
</table>
<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">Henrik Zetterberg</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>University of Gothenburg<br>UCL</td>
</tr>
<tr>
<td class="label">Country</td>
<td>Sweden/UK</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>200</td>
</tr>
<tr>
<td class="label">ORCID</td>
<td><a href="https://orcid.org/0000-0003-3939-6464" target="_blank">0000-0003-3939-6464</a></td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/als)</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>[Biomarkers](/mechanisms/biomarkers-ad), Neurofilament, [Tau](/mechanisms/tau-pathology), [Alpha-synuclein](/mechanisms/alpha-synuclein)</td>
</tr>
</table>
Henrik Zetterberg is a leading researcher in the field of neurodegenerative diseases, affiliated with University of Gothenburg and UCL. Their research focuses on Biomarkers, Neurofilament, [Tau](/proteins/tau), [Alpha-synuclein](/proteins/alpha-synuclein), with particular emphasis on [Alzheimer's Disease](/diseases/alzheimers-disease) and [Parkinson's Disease](/diseases/parkinsons-disease) and ALS. With an h-index of 200, Zetterberg is among the most cited researchers in the neuroscience field["@orcid2026"].
Zetterberg's work spans multiple aspects of neurodegeneration, contributing to our understanding of the molecular mechanisms that underlie diseases such as Alzheimer's Disease and Parkinson's Disease and ALS. Their research group has made significant contributions to the fields of Biomarkers, Neurofilament, [Tau](/proteins/tau), Alpha-synuclein, publishing in high-impact journals including leading neuroscience journals.
Based at University of Gothenburg and UCL, Zetterberg collaborates with researchers across multiple institutions worldwide, working to advance therapeutic strategies for neurodegenerative conditions.
The work frequently sits at the interface of discovery science and implementation, using study designs that can be transferred from observational cohorts to interventional studies. This makes the profile especially relevant for NeuroWiki pages that connect molecular mechanisms to treatment strategy, trial design, and patient stratification.
The program also supports comparative interpretation across related disorders, helping distinguish disease-general stress biology from disease-specific pathomechanisms. That distinction is important for mechanistic ranking and for selecting therapeutic targets with realistic translational potential.
This orientation improves actionability of mechanistic knowledge graphs because it links entities and pathways to measurable clinical decisions. Pages connected to this profile should therefore prioritize explicit mechanism-to-outcome chains, with clear assumptions and evidence quality labels.
Recent PubMed-indexed publications (2024-present):
[Kaj Blennow](/researchers/kaj-blennow), [John Hardy](/researchers/john-hardy)